Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,263 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Asthma
Interventions: Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Healthy People
Interventions: Grape Powder; Other
Lead sponsor: California State Polytechnic University, Pomona; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Pomona, California

Conditions: Hereditary Angioedema (HAE)
Interventions: C1 esterase inhibitor [human] liquid, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more

Conditions: Healthy
Interventions: transdermal nicotine patch (7mg); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions: NBI-921352, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more

Conditions: Grade 1 Endometrial Endometrioid Adenocarcinoma, Grade 2 Endometrial Endometrioid Adenocarcinoma, Complex Atypical Endometrial Hyperplasia
Interventions: Depot medroxyprogesterone acetate, Placebo; Drug · Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Menopause, Irritable Mood
Interventions: Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 59 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Depression, Major Depressive Disorder
Interventions: Nitrous Oxide, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 42
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Major Depressive Disorder
Interventions: Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Alcohol Abuse, Impulsive Behavior
Interventions: Tolcapone, Placebo; Drug
Lead sponsor: Jennifer Mitchell; Other
Eligibility: 21 Years to 40 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Berkeley, California • San Francisco, California

Conditions: Frailty
Interventions: Magnetic Mitohormesis Therapy; Other
Lead sponsor: Auburn University; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Breast Cancer, Non-Hodgkin's Lymphoma
Interventions: Mesna, Saline, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Mara Chambers; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: HCV Infection
Interventions: ABT-333 Tablet, Placebo, ABT-333 Capsule; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Colorectal Cancer
Interventions: Ramucirumab, Placebo, Irinotecan, Folinic Acid, 5-Fluorouracil; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 92
States / cities: Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more

Conditions: Obstructive Sleep Apnea, Sleep-disordered Breathing
Interventions: Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition; Other · Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Interventions: Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion; Biological · Drug · Other
Lead sponsor: CatalYm GmbH; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Irvine, California • Los Angeles, California • Orange, California + 4 more

Conditions: Spatial Navigation
Interventions: Active 10-Hz TMS to the parietal cortex, Active single pulse TMS to the parietal cortex, Sham 10-Hz TMS to the right parietal cortex, Sham single-pulse rTMS the rigt parietal cortex; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Triple Negative Breast Neoplasms
Interventions: Capivasertib, Paclitaxel, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 923 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 22
States / cities: Whittier, California • Fort Myers, Florida • Miami, Florida + 18 more

Conditions: Hypoglycemia Unawareness
Interventions: Carvedilol 3.125 mg, Carvedilol 2.5 mg, Placebo capsule; Drug
Lead sponsor: Owen Chan, PhD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Bronchopulmonary Dysplasia
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: Hubert Ballard; Other
Eligibility: Up to 72 Hours
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy Volunteer
Interventions: ABBV-CLS-616, Placebo, Itraconazole; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more

Conditions: Spinal Cord Injuries
Interventions: Hypoxia via Hypoxico Hyp-123, Sham via Hypoxico Hyp-123; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

The Effects of Freeze-Dried Whole Grape Powder on Chronic Disease and Cardiovascular Risk Factors-a Pilot Study

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Nicotine Patch, Blood Flow and Oxidative Stress Study

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

Estrogen Variability and Irritability During the Menopause Transition

Nitrous Oxide as Treatment for Major Depression - a Pilot Study

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users

Pilot-testing the Effect of Magnetic Mitohormesis Therapy for Treating Frailty in Older Adults

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

A Study in Second Line Metastatic Colorectal Cancer

Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Modulating Goal-directed Navigation Using Noninvasive Brain Stimulation

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Carvedilol in Treating Hypoglycemia Unawareness

Trial II of Lung Protection With Azithromycin in the Preterm Infant

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Intermittent Hypoxia to Enhance Motor Function After Spinal Cord Injury